Connection

THOMAS MONATH to Encephalitis, Japanese

This is a "connection" page, showing publications THOMAS MONATH has written about Encephalitis, Japanese.
Connection Strength

2.408
  1. Japanese Encephalitis: Risk of Emergence in the United States and the Resulting Impact. Viruses. 2023 12 28; 16(1).
    View in: PubMed
    Score: 0.880
  2. Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immunol. 2009 Jul; 16(7):1052-9.
    View in: PubMed
    Score: 0.320
  3. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
    View in: PubMed
    Score: 0.216
  4. Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol. 2002; 267:105-38.
    View in: PubMed
    Score: 0.192
  5. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999 May 10; 257(2):363-72.
    View in: PubMed
    Score: 0.159
  6. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999 Apr 09; 17(15-16):1869-82.
    View in: PubMed
    Score: 0.159
  7. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine. 1997 Oct; 15(14):1494-502.
    View in: PubMed
    Score: 0.143
  8. Japanese encephalitis--a plague of the Orient. N Engl J Med. 1988 Sep 08; 319(10):641-3.
    View in: PubMed
    Score: 0.076
  9. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine. 2004 Sep 09; 22(27-28):3722-6.
    View in: PubMed
    Score: 0.058
  10. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res. 2003; 61:469-509.
    View in: PubMed
    Score: 0.051
  11. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
    View in: PubMed
    Score: 0.048
  12. Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci. 2001 Dec; 951:1-12.
    View in: PubMed
    Score: 0.048
  13. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000 Feb; 74(4):1742-51.
    View in: PubMed
    Score: 0.042
  14. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001 Jan; 75(2):934-42.
    View in: PubMed
    Score: 0.011
  15. Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances. J Nat Prod. 1992 Nov; 55(11):1569-81.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.